Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Dundee upgrades AEterna to Buy

|Includes: AEterna Zentaris, Inc. (AEZS)

Dundee Securities upgraded AEterna Zentaris (NASDAQ:AEZS TSX:AEZ) to “buy” from “neutral” but kept its price target at $2 (U.S.), based on recent stock weakness and removal of a financing overhang.

Analyst David Martin writes that a financing issue this week should support operations for about 20 months based on an expected burn rate of $2.3 million per month.

“Optimally, AEterna would have completed a license deal for perifosine in ex-U.S. markets, and/or for its AEZS-108 drug, then issue equity at a higher stock price.  Nonetheless, the financing eliminates an overhang, as it should provide a funding runway to Phase 3 results for perifosine in multiple myeloma and colorectal cancer.  Both trials are expected to report results in the second half of 2011,” he said in a new report.



Disclosure: No positions